Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950123-07-004208
Filing Date
2007-03-21
Accepted
2007-03-21 16:11:39
Documents
8
Period of Report
2006-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K y32284e10vk.htm 10-K 600105
2 EX-10.11: LICENSE AGREEMENT y32284exv10w11.htm EX-10.11 93192
3 EX-23.1: CONSENT y32284exv23w1.htm EX-23.1 1942
4 EX-31.1: CERTIFICATION y32284exv31w1.htm EX-31.1 7330
5 EX-31.2: CERTIFICATION y32284exv31w2.htm EX-31.2 7607
6 EX-32.1: CERTIFICATION y32284exv32w1.htm EX-32.1 3412
7 EX-32.2: CERTIFICATION y32284exv32w2.htm EX-32.2 3437
8 GRAPHIC y32284g0607701.gif GRAPHIC 6146
  Complete submission text file 0000950123-07-004208.txt   727076
Mailing Address 555 MADISON AVENUE, 25TH FLOOR NEW YORK NY 10022
Business Address 555 MADISON AVENUE, 25TH FLOOR NEW YORK NY 10022 212-716-1810
Innovive Pharmaceuticals, Inc. (Filer) CIK: 0001337223 (see all company filings)

EIN.: 743123261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-51534 | Film No.: 07709308
SIC: 2836 Biological Products, (No Diagnostic Substances)